A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction

Phase 2

Completed

• Conditions: Myocardial Infarction
• Interventions: Drug: Fulacimstat (BAY1142524); Drug: Placebo

• Registration Number: NCT02976467
• Lead Sponsor: Bayer

Brief Summary

The purpose of the trial is the analysis of safety and efficacy of the chymase inhibitor BAY1142524 at a dose of 25 mg BID in comparison to placebo using a 6 months treatment period in patients with left-ventricular (LV) dysfunction after myocardial infarction (MI). BAY1142524 or placebo will be given on top of evidence-based standard of care for left-ventricular dysfunction after myocardial infarction. Primary objective is the analysis of first signs of efficacy as determined by favourable changes in functional parameters of adverse cardiac remodelling (i.e. endsystolic and enddiastolic volume index, ejection fraction). Secondary objective is the analysis of safety and tolerability as evidenced by the incidence and severity of adverse events. 30 patients have to complete treatment with verum and 30 patients have to complete treatment with placebo.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-11-24
• Study First Submitted QC: 2016-11-24
• Study First Posted: 2016-11-29
• Study Start: 2016-12-30
• Primary Completion: 2018-07-31
• Study Completion: 2018-09-04
• Status Verified: 2019-08
• Last Update Submitted: 2019-08-30
• Last Update Posted: 2019-09-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 107

Inclusion Criteria

• Patients with first ST elevation myocardial infarction (STEMI) treated with primary percutaneous intervention (PCI) or thrombolysis within 24 hours after symptom onset

• Diagnosis of STEMI requires the presence of the following three criteria:

  • Typical clinical symptoms such as chest pain, shortness of breath for more than 20 minutes related to the myocardial infarction
  • New ST elevation indicating myocardial infarction
  • Significant elevation in troponin T or I with at least one value above the 99th percentile upper reference limit (URL) and/or elevation creatine kinase (CK) and creatine kinase MB (6-10% of total CK)

• At the screening period, on day 5 to 9 after MI, patients have to have a LVEF ≤ 45% and an infarct size >10% LV mass (as measured by LGE-MRI, central-blinded evaluation)

Read More

Exclusion Criteria

• Contraindication to perform contrast-enhanced cardiac MRI
• LVEF < 20%
• History of heart failure or LVEF < 50% before occurrence of the first STEMI
• Infarct size > 45% (g/g; LV mass) between 5 and 9 days after myocardial infarction
• NYHA (New York Heart Association) class IV at randomization
• Any planned cardiac intervention after baseline MRI or any other planned operations
• Non-ischemic causes for cardiomyopathy
• Diagnosis of atrial fibrillation
• Systolic blood pressure < 100 mm Hg or > 180 mm Hg; diastolic blood pressure < 50 mm Hg or >110 mm Hg, heart rate < 50 or >100 beat/minute; mean of triplicate values at randomization
• Clinically relevant hepatic dysfunction

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Fulacimstat (BAY1142524)	Fulacimstat (BAY1142524)	30 patients with left-ventricular dysfunction after acute myocardial infarction
Placebo	Placebo	30 patients with left-ventricular dysfunction after acute myocardial infarction

Primary Outcome Measures

Name	Time	Method
Change in left-ventricular ejection fraction (LVEF)	At 6 months
Change in end diastolic volume index (EDVI)	At 6 months
Change in end systolic volume index (ESVI)	At 6 months

Secondary Outcome Measures

Name	Time	Method
Number of patients with serious adverse events	Up to 7 months
Number of patients with adverse events	Up to 7 months